The Indian diagnostic industry is riding a long-term structural uptrend. Rising lifestyle diseases, increasing healthcare awareness, deeper insurance penetration, and government-backed healthcare initiatives have transformed diagnostics from a niche service into a core pillar of preventive and curative healthcare.
Against this backdrop, Star Imaging and Path Lab, a NABL-accredited diagnostics chain, has quietly built a three-pronged business model spanning B2C, B2G, and B2B segments. With a 47-year legacy that began as a small X-ray clinic in West Delhi, the company is now gearing up for its BSE SME listing. Many investors are now asking — “Should I invest in this IPO?” This Star Imaging IPO review will address all your doubts by covering its business model, revenue streams, financial performance, peer comparison, SWOT analysis, and growth strategy. Let’s explore it in detail.
2. Star Imaging IPO Snapshot
| Item | Details |
|---|---|
| IPO Dates | 8 – 12 Aug 2025 |
| Price Band | INR 135–142 per share |
| Fresh Issue | 39,20,000 shares (~INR 52.92–55.66 Cr) |
| Offer for Sale | 9,72,000 shares (~INR 13.12–13.80 Cr) |
| Total Issue Size | 48,92,000 shares (~INR 66.04–69.47 Cr) |
| Lot Size | 1,000 shares |
| Minimum Bid | 2,000 shares (INR 2,84,000) |
| Retail Allocation | 35% |
| Listing | BSE SME |
The proceeds will primarily go into INR 25 crore for working capital, INR 12 crore for debt repayment, and INR 5.14 crore for refurbished medical equipment acquisition. This targeted use of funds indicates management’s focus on strengthening operational capacity and reducing leverage, rather than purely chasing aggressive expansion.
3. Company Snapshot
Star Imaging’s corporate journey is a story of gradual capacity building and diversification.
- 1978: Started as Janta X-Ray Clinic, offering manual X-ray and basic pathology tests.
- 2004: Incorporated as Star Imaging & Path Lab to consolidate services under one roof.
- 2011: Acquired Janta X-Ray Clinic, M/s Star Imaging & Path Lab, and M/s Star Health Care.
- 2024: Converted to a public limited company ahead of IPO.
Today’s Footprint:
- 4 Retail Diagnostic Centres in Delhi — full-service facilities catering to individual patients.
- 19 PPP Centres in Delhi, Uttar Pradesh, and Nashik — operated in government hospitals under public-private partnership (B2G model).
- 211 full-time employees supported by a network of consultants.
- Central Tele-Radiology Hub — enabling high-volume, cost-efficient image reporting for all locations.
What sets Star Imaging apart is its hub-and-spoke model. High-end imaging equipment like MRI and CT scanners are concentrated in hub facilities (like Tilak Nagar, Delhi), while smaller collection or PPP centres channel patient volume to these hubs for advanced imaging and report generation.
4. Star Imaging IPO Review: Business Model
a) B2C – Retail Diagnostics
This segment caters to direct walk-in and home-collection patients in the Delhi region.
- Network: 4 full-service retail centres strategically located to cover dense residential zones.
- Services: Radiology, pathology, cardiology, neurology under one roof.
- FY25 Revenue Share: 36.24% (~INR 30.16 crore).
- Drivers: Brand recall built over decades, NABL accreditation ensuring quality assurance, convenience through home sample collection.
- Challenge: High dependence on Delhi market — no current B2C presence beyond NCR.
b) B2G – Public-Private Partnerships
Star Imaging’s B2G model is its growth engine, contributing over 57% of revenue in FY25.
- Scope: Long-term PPP contracts with state and municipal hospitals in Delhi, Uttar Pradesh, and Nashik.
- Services Provided: Installation and operation of MRI, CT scanners, and associated radiology services; provision of skilled manpower; equipment maintenance.
- Revenue Share FY25: INR 47.84 crore.
- Strength: High patient throughput with predictable demand from government hospital footfalls.
- Risk: Renewal dependency on government policies, payment timelines, and tender cycles.
c) B2B – Private Hospital Tie-Ups
Star Imaging partners with 40 empanelled private hospitals in Delhi to provide diagnostic services at agreed discounted rates.
- FY25 Revenue Share: 6.29% (~INR 5.23 crore).
- Strategic Role: While smaller in contribution, it acts as a feeder for B2C and strengthens institutional relationships.
- Growth Potential: Extending this model to Tier-II cities and high-growth healthcare hubs can increase penetration without heavy capex.
5. Service Portfolio
Star Imaging positions itself as a full-spectrum diagnostics player, reducing dependency on any single service line.
Radiology (INR 66.96 crore FY25)
- MRI: GE Optima CT660 with cardiac imaging capability.
- CT Scan: Multi-slice imaging, angiography.
- Mammography: Fujifilm AMULET with 3D tomosynthesis.
- 4D/5D Ultrasound: Samsung 5D V6 for obstetric & specialized imaging.
- Bone Mineral Densitometry: GE DEXA for osteoporosis and metabolic health assessment.
- Dental OPG: Cone Beam 3D imaging for oral diagnostics.
Pathology (INR 14.13 crore FY25)
- Biochemistry, hematology, histopathology, cytopathology, microbiology, immunology.
- Automated high-throughput analyzers integrated with EMR for faster turnaround.
Cardiology & Neurology
- ECG, stress TMT, echocardiography, Holter monitoring, EEG, nerve conduction studies.
- Advanced neuro-diagnostic services like Visual Evoked Potential (VEP) and Electromyography (EMG).
Specialized Testing
- Fibro Scan for liver stiffness analysis.
- Uroflowmetry for urinary tract diagnostics.
- Sleep studies for apnea and related disorders.
This diverse portfolio helps the company cater to both high-volume routine diagnostics and high-margin specialized tests, enhancing resilience against demand fluctuations.
6. Financial Performance & Efficiency
Star Imaging’s financials reflect a remarkable turnaround from a post-COVID slump to a high-margin, efficient operation. The company has not only scaled revenues but has also achieved significant operating leverage by optimising costs and improving utilisation of its diagnostic infrastructure.
| Metric | FY23 | FY24 | FY25 | Key Insights |
|---|---|---|---|---|
| Revenue from Operations | 58.37 | 78.50 | 83.24 | 34.5% jump in FY24 due to post-COVID recovery & PPP scale-up; growth moderated to 6% in FY25 |
| EBITDA | 5.81 | 22.34 | 28.47 | Margins boosted by cost rationalisation & closure of underperforming centres |
| EBITDA Margin (%) | 9.95 | 28.46 | 34.21 | Significant jump from low COVID base, sustained above 30% |
| PAT | 0.57 | 12.45 | 15.96 | From near-breakeven to healthy profitability within two years |
| ROCE (%) | 5.74 | 29.54 | 29.83 | Strong capital efficiency maintained post-turnaround |
| Debt/Equity | 1.40 | 0.98 | 0.69 | Gradual deleveraging ahead of IPO |
7. Star Imaging IPO Review: Operational Strengths & Competitive Edge
- High Infrastructure Entry Barrier: MRI, CT, and BMD infrastructure demands high capital investment and specialist manpower. This naturally limits competition from small-scale regional players.
- NABL Accreditation & Quality Standards: Accreditation enhances trust with both institutional and retail customers, and is a key qualifier for government tenders and hospital tie-ups.
- Government Contract Stickiness: PPP contracts in multiple states provide consistent patient volumes and revenue visibility. These partnerships also strengthen Star Imaging’s positioning as a reliable healthcare services partner.
- Hub-and-Spoke Tele-Radiology Model: By centralising image reporting through its tele-radiology hub, the company maximises utilisation of high-end equipment, reduces turnaround time, and scales efficiently without duplicating expensive infrastructure.
8. Star Imaging IPO Peer Comparison
| Metric | Star Imaging (Post-Issue) | Chandan Healthcare | Vijaya Diagnostic | Metropolis Healthcare |
|---|---|---|---|---|
| EBITDA (INR Cr) | 28.60 | 41.33 | 273.22 | 273.22 |
| EBITDA Margin (%) | 34.25 | 17.96 | 40.10 | 40.09 |
| PAT Margin (%) | 19.10 | 10.22 | 21.10 | 10.93 |
| EPS (INR) | 9.16 | 9.07 | 14.60 | 28.00 |
| P/E (X) | 15.5 | 27.6 | 72.5 | 75.2 |
| P/S (X) | ~1.70 | 2.66 | 15.3 | 7.90 |
| P/B (X) | 4.07 | 4.98 | 13.7 | 7.91 |
| ROE (%) | 33.84 | 19.18 | 18.07 | 10.93 |
| ROCE (%) | 23.10% | 16.45 | 15.29 | 12.20 |
| Debt-to-Equity (X) | 0.69 | 0.39 | 0.40 | 0.15 |
| Current Ratio (X) | 1.96 | 1.94 | 1.89 | 0.94 |
1. Profitability Performance
- EBITDA Margins:
- Vijaya (40.10%) and Metropolis (40.09%) lead, followed closely by Star Imaging (34.25%).
- Chandan lags with 17.96%, indicating higher operating costs and lower pricing power.
- PAT Margins:
- Vijaya (21.10%) highest, then Star Imaging (19.10%), Metropolis (10.93%), Chandan (10.22%).
- Star Imaging’s profitability is exceptional given its smaller scale.
- Return Ratios:
- ROE: Star Imaging (33.84%) highest, then Chandan (19.18%), Vijaya (18.07%), Metropolis (10.93%).
- ROCE: Star Imaging (23.10%) highest, showing efficient capital deployment.
2. Balance Sheet Strength
- Debt-to-Equity:
- Metropolis (0.15) lowest leverage, Vijaya (0.40), Chandan (0.39), Star Imaging (0.69).
- Star Imaging’s gearing is higher than peers but still manageable given its interest coverage of 9.57x.
- Liquidity:
- Current Ratios are healthy across peers (~1.8–2.0) except Metropolis (0.94), indicating lower short-term liquidity cushion.
3. Valuation Perspective (Post-Issue for Star Imaging)
- P/E:
- Star Imaging: 15.5x (post-issue, EPS: INR 9.16) — significantly cheaper than Chandan (27.6x), Vijaya (72.5x), and Metropolis (75.2x).
- P/S:
- Star Imaging: ~1.70x (post-issue) — lowest in peer set.
- Chandan: 2.66x, Vijaya: 15.3x, Metropolis: 7.90x.
- P/B:
- Star Imaging: 4.07 vs Chandan (4.98), Vijaya (13.7), Metropolis (7.91).
- Lower than high-premium listed peers despite strong ROE.
4. Investment Takeaways
- Operational Efficiency: Star Imaging has best-in-class ROE and third-highest margins despite its small size.
- Attractive Valuation: At 15.5x P/E and ~1.70x P/S, it trades at a deep discount to peers, offering potential valuation re-rating as it scales.
- Risks: Smaller scale, higher debt-to-equity than top peers, and regional concentration could limit immediate expansion pace.
- Upside Potential: If Star Imaging can expand beyond NCR and sustain margins, the gap in valuation with Chandan, Vijaya, and Metropolis could narrow, providing significant investor upside
8. Star Imaging IPO SWOT Analysis
| Strengths Diversified multi-segment business model (B2C, B2G, B2B). High operating margins supported by cost-optimised operations. Established PPP contracts ensuring steady patient inflow. Advanced diagnostic infrastructure and NABL accreditation. | Weaknesses Geographic concentration — retail business limited to Delhi NCR. Working capital pressure due to delayed PPP receivables. |
| Opportunities Expansion into Tier-II and Tier-III cities through asset-light models. Growth in molecular diagnostics and genomics testing. Increasing government healthcare budgets driving PPP demand. | Threats Technological obsolescence in imaging equipment. Policy or regulatory changes affecting PPP renewals. Intensifying competition from large diagnostic chains. |
9. Growth Strategy
- Geographic Expansion: The company plans to extend its footprint into under-served regions, especially Tier-II and Tier-III cities, leveraging PPP opportunities and potentially adopting franchise or asset-light models for B2C expansion.
- Service Portfolio Enhancement: Investment in molecular diagnostics, genomics, and chronic disease management will deepen service capabilities and open higher-margin revenue streams.
- Strengthening PPP Portfolio: Leveraging its proven execution record to win more state-level diagnostic projects, reinforcing leadership in the public healthcare diagnostics segment.
- Private Sector Partnerships: Expanding B2B hospital tie-ups beyond Delhi, targeting private healthcare hubs across India to diversify and grow institutional revenues.
10. Star Imaging IPO Review: Closing Viewpoint
From an investment perspective, Star Imaging’s business model offers a balanced blend of stability and scalability. The PPP segment delivers predictable volumes, the B2C arm builds brand equity, and the B2B vertical establishes institutional credibility. The transformation in EBITDA margins — from ~10% in FY23 to 34% in FY25 — underscores effective management execution.
However, investors should track the company’s geographic dependency and working capital intensity due to PPP receivables. The IPO’s focus on debt reduction and infrastructure upgrade should strengthen its balance sheet, improve cash flows, and position it for the next growth phase.
In India’s expanding diagnostics market, Star Imaging’s hub-and-spoke, multi-segment model positions it well to capture both government-led and private healthcare demand — provided it continues to manage receivables and diversify beyond NCR.
For more details related to IPO GMP, SEBI IPO Approval, and Live Subscription stay tuned to IPO Central.